- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00633958
A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors (FLT)
A Pilot, Non-Therapeutic NeuroImaging Study of 18F-FLT in Pediatric Patients With Newly Diagnosed Central Nervous System Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will undergo standard pre-diagnostic imaging of the sites of disease using standard MRI techniques. If disease is suspected in both the brain and spine, then both imaging modalities should be obtained. This imaging should be obtained no more than 21 days before surgical resection. As close as possible to the completion of the MRI scans, patients will undergo 18F-FLT imaging using a single administration of tracer, and PET image acquisition at four different time points (baseline, 1 hr post injection, 2 hrs post injection and 4-6 hours post injection). A whole body PET scan (top of the head to mid thigh) will be performed immediately after injection (PET acquisition #1). These data will be acquired with a 2 minute emission and a 2 minute transmission scan at each bed position. Following this acquisition, the subject will empty his or her bladder. At 45 minutes post-injection, a brain and/or spine (body) PET scan will be acquired with a 10 min emission scan and a 5 min transmission scan (PET acquisition #2). This scan will include all areas of suspected tumor (brain, spine, or brain and spine). Following PET acquisition #2, a whole body PET scan will be acquired according to the same protocol as above (PET acquisition #3). If possible, a final whole body scan will be acquired 4-6 h post-injection (PET acquisition #4). All PET acquisitions will be acquired in 3D mode and reconstructed with the FORE re-binned OSEM algorithm with measured attenuation correction. Blood samples will be obtained at the completion of each whole body scan. Patients will receive the dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Patients will then undergo maximal surgical resection. Pieces from different areas of the tumor will be marked for correlation to imaging studies when possible. Tumor samples will undergo standard immunohistochemical analysis for cellular activation including mitotic index and MIB-1 proliferation staining.
Serial blood draws will also be obtained at four different time points (baseline, 1 hr post injection, 2 hrs post injection, and 4-6 hours post injection) to evaluate clearance of 18F-FLT from the blood.
For the biodistribution, the 3D regions of interest (ROIs) will be drawn about each major organ that is identified on the whole body scans. This will be performed on each of the whole body scans and a time activity curve will be generated. The residence time for each organ will be determined. The blood data will be pipetted and counted for estimates of activity in the blood and bone marrow. For the brain and/or spine images, the PET data will be registered to the subjects' MRI. The PET scan will be graded on a subjective 4-point scale. 3D ROIs will be drawn around the tumor. In addition, an analogous ROI will be drawn in normal brain background and about the whole brain for comparison. For the tumor, tumor-to-background, tumor-to-whole brain ratios will be determined. In addition, standard uptake values (SUVs) will be determined for the tumor and background.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Children's Hospital Boston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pediatric patients with newly diagnosed central nervous system tumors undergoing planned surgical resection within 21 days.
- Patients should be < 21 years of age at the time of diagnosis.
- Patients should be capable of achieving imaging without the need for sedation or anesthesia.
- Karnofsky Performance Status ≥ 50. For infants, the Lansky play scale ≥ 50% can be substituted.
- Patients must not be pregnant or nursing.
- Signed Informed Consent.
- Patients receiving steroids and/or anti-seizure medications are eligible for this study.
Exclusion Criteria:
- Prior radiation therapy and/or chemotherapy are not permitted.
- Active infection
- Pregnancy or breast feeding
- Serious concurrent medical illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 18F-FLT
All subjects will receive 18F-FLT prior to PET imaging.
|
Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures.
Dosing will be based on age.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the distribution, localization and kinetics of localization of 18F-FLT in pediatric patients with central nervous system tumors
Time Frame: Assessed shortly after subjects undergo neuroimaging
|
Assessed shortly after subjects undergo neuroimaging
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To correlate the activity of administering 18F-FLT in newly diagnosed pediatric brain tumor patients to standard immunohistochemical markers of cellular activation and MRI imaging
Time Frame: Assessed shortly after subjects undergo neuroimaging
|
Assessed shortly after subjects undergo neuroimaging
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Mark Kieran, MD, Dana-Farber Cancer Institute/Children's Hospital Boston
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-303
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumors of the Central Nervous System
-
University of FloridaCompletedCentral Nervous System TumorsUnited States
-
Centre Francois BaclesseActive, not recruitingProton Therapy | Benign Brain TumorsFrance
-
Monte Verde SAFLENI Instituto de Rehabilitación y Educación Terapéutica, BA, Argentina.; Bioanalytical... and other collaboratorsCompletedBrain Neoplasms, Malignant, PrimaryArgentina
-
Central Hospital, Nancy, FranceRecruitingMeningeal Melanocytoma | Meningeal Melanomatosis | Meningeal Melanocytosis | Meningeal MelanomaFrance
-
I.M. Sechenov First Moscow State Medical UniversityCompletedTumors of the Central Nervous System | Childhood Cancer SurvivorsRussian Federation
-
Legacy Health SystemDUSA Pharmaceuticals, Inc.Unknown
-
Burzynski Research InstituteTerminatedRhabdoid Neoplasm of CNSUnited States
-
Immune Oncology Research InstituteRecruitingEmbryonal TumorArmenia, Hungary, Canada, Peru, Iran, Islamic Republic of, Italy, Taiwan, India, Mexico
-
Beijing Sanbo Brain HospitalRecruiting
-
National Cancer Institute (NCI)Active, not recruitingBrain Cancer | Brain Tumor | Neoplasm | Spine Cancer | Spine TumorUnited States
Clinical Trials on 18F-FLT
-
University of Texas Southwestern Medical CenterWithdrawnSolid TumorUnited States
-
University of UtahBlue Earth DiagnosticsTerminatedBrain TumorUnited States
-
Memorial Sloan Kettering Cancer CenterWithdrawnHistologically-confirmed MalignanciesUnited States
-
Frederick Daniel GrantDana-Farber Cancer InstituteCompleted
-
National Cancer Centre, SingaporeRecruitingCervix Cancer | Image, BodySingapore
-
Abramson Cancer Center of the University of PennsylvaniaCompleted
-
University of IowaNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedHead and Neck Neoplasms | Mouth Neoplasms | Oropharyngeal Neoplasms | Laryngeal NeoplasmsUnited States
-
National Taiwan University HospitalUnknown
-
Hamad Medical CorporationUnknownEssential Thrombocythemia | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic StageQatar
-
Hamad Medical CorporationTerminatedPolycythemia Vera | Essential Thrombocythemia | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic StageQatar